Cessatech reports last subject dosed in bioavailability trial of lead product candidate
Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports last subject dosed ahead of timelines. Primary aim of the trial is to demonstrate drug-exposure following nasal administration of CT001 relative to the IV injection of the approved analgesic drugsCessatech A/S announces that the 12-subject bioavailability trial has had the last subject dosed in this randomized three-treatment, three-period, single dose crossover trial. The trial investigates the absorption of CT001 nasal spray across nasal mucosa (also known as bioavailability)